Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab

Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamenca, Salamenca, Spain, talks to us about the role of immune checkpoint inhibitors in the treatment of multiple myeloma (MM). The anti-PD1/PD-L1 monoclonal antibody, pembrolizumab, and the anti-PD-L1 drug, durvalumab, have been shown to have acceptable safety profiles and effectiveness in clinical trials evaluating their clinical benefit in treating MM and their results have been presented at the ASCO congress. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.